Pedagogical conditions for teaching future employees of the medical industry for the diagnosis and treatment of multiple myeloma
DOI:
https://doi.org/10.25726/k6984-7942-2039-dKeywords:
Multiple myeloma, myeloma, plasmocytoma, genetic changes.Abstract
The theoretical training of future doctors in Russia has been and remains at a satisfactory level, but the practical training of general practitioners and other specialties has deteriorated significantly, which is influenced by subjective and objective factors. Although the theoretical training of the sixth-year students is still at a satisfactory level, the practical training of doctors after graduation is far behind. This is due to the fact that the departments of internal medicine, which lay the foundations for the training of a doctor of any specialty, are very poorly equipped with diagnostic, scientific and insufficiently — educational equipment that should be used in the educational process. Every year, more than 10 thousand people of the "specialist" (Master's) educational level graduate from the medical and pharmaceutical education institutions of the Ministry of Health. At the same time, there is no effective system for predicting the need for medical personnel yet. The existing registers of medical workers do not reflect the real picture, because they are built on Soviet principles. The reform of the financing of the health care system, launched in 2017, will lead to a change in the number and functional responsibilities of medical personnel. Accordingly, any long-term forecasting will require adjustments. Multiple myeloma-paraproteinemic hemoblastosis, which is characterized by malignant tumor proliferation of plasma cells of a single clone with hyperproduction of monoclonal immunoglobulin or free monoclonal chains of immunoglobulins, is a fairly complex disease that requires significant diagnostic and practical efforts for appropriate treatment. That is why the importance of teaching the diagnosis and treatment of multiple myeloma to medical students is an urgent task.
References
Bhutani, M., Foureau, D. M., Atrash, S., Voorhees, P. M., & Usmani, S. Z. (2020). Extramedullary multiple myeloma. Leukemia, 34(1). https://doi.org/10.1038/s41375-019-0660-0
Campbell, J. P., Heaney, J. L. J., Pandya, S., Afzal, Z., Kaiser, M., Owen, R., … Drayson, M. T. (2017). Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. The Lancet Haematology, 4(12), e584–e594. https://doi.org/10.1016/S2352-3026(17)30209-0
Dabbah, M., Attar-Schneider, O., Zismanov, V., Matalon, S. T., Lishner, M., & Drucker, L. (2016). Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation. Journal of Leukocyte Biology, 100(4), 761–770. https://doi.org/10.1189/jlb.3A1115-510RR
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020). Evaluating daratumumab in the treatment of multiple myeloma: Safety, efficacy and place in therapy. Cancer Management and Research, 12, 7891–7903. https://doi.org/10.2147/CMAR.S212526
Feng, M., Luo, X., Gu, C., & Fei, J. (2015). Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. Journal of Drug Targeting, 23(1), 59–66. https://doi.org/10.3109/1061186X.2014.951653
Kabir, A. L., Rahman, M. J., Begum, M., Dipta, T. F., Baqui, M. N., Aziz, A., … Habib, M. A. (2012). Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma. Mymensingh Medical Journal : MMJ, 21(1), 114–119.
Kunacheewa, C., & Manasanch, E. E. (2020). High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Practice and Research: Clinical Haematology, 33(1). https://doi.org/10.1016/j.beha.2020.101152
Lee, W., Chen, R. C., Swaminathan, S. K., & Ho, C. L. (2019). Extramedullary multiple myeloma with central nervous system and multiorgan involvement: Case report and literature review. Journal of Radiology Case Reports, 13(12), 1–12. https://doi.org/10.3941/jrcr.v13i12.3784
Li, Q., & Liu, Z.-S. (2013). Source and differentiation of multiple myeloma stem cells. Chinese Journal of Tissue Engineering Research, 17(10), 1891–1895. https://doi.org/10.3969/j.issn.2095-4344.2013.10.028
Manier, S., Kawano, Y., Bianchi, G., Roccaro, A. M., & Ghobrial, I. M. (2016). Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Current Opinion in Hematology, 23(4), 426–433. https://doi.org/10.1097/MOH.0000000000000259
Rajkumar, S. V, & Kyle, R. A. (2013). Diagnosis and treatment of multiple myeloma. Neoplastic Diseases of the Blood. https://doi.org/10.1007/978-1-4614-3764-2_33
Shpilberg, K. A., Esses, S. J., Fowkes, M. E., Chari, A., Sacher, M., & Naidich, T. P. (2015). Imaging of extraosseous intracranial and intraspinal multiple myeloma, including central nervous system involvement. Clinical Imaging, 39(2), 213–219. https://doi.org/10.1016/j.clinimag.2014.11.017
Xu, L., Mohammad, K. S., Wu, H., Crean, C., Poteat, B., Cheng, Y., … Srour, E. F. (2016). Cell adhesion molecule CD166 drives malignant progression and osteolytic disease in multiple myeloma. Cancer Research, 76(23), 6901–6910. https://doi.org/10.1158/0008-5472.CAN-16-0517
Yang, Y., Wang, S., Li, J., Qi, S., & Zhang, D. (2017). CUL4A as a marker and potential therapeutic target in multiple myeloma. Tumor Biology, 39(7), 1–7. https://doi.org/10.1177/1010428317703923
Zhang, X. Y., Rajagopalan, D., Chung, T.-H., Hooi, L., Toh, T. B., Tian, J. S., … Chow, E. K.-H. (2020). Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma. Experimental Hematology and Oncology, 9(1). https://doi.org/10.1186/s40164-020-00164-4
